Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 5/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.33 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.33 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15428838 | 0.85 | MAPT (0.38) | SIGMAR1MAPTKDM4EMEN1ALDH1A1 | |
| SCHEMBL14594813 | 0.78 | SIGMAR1 (0.41) | SIGMAR1SLC6A3SLC6A2SLC6A4 | |
| SCHEMBL23508979 | 0.72 | SIGMAR1 (0.35) | SIGMAR1MAPTKDM4EMEN1ALDH1A1 | |
| SCHEMBL20384101 | 0.72 | SIGMAR1 (0.35) | SIGMAR1MAPTKDM4EMEN1ALDH1A1 | |
| SCHEMBL20384109 | 0.72 | MAPT (0.37) | SIGMAR1MAPTKDM4EMEN1ALDH1A1 | |
| SCHEMBL6593632 | 0.69 | — | — | |
| SCHEMBL14594798 | 0.67 | MAPT (0.36) | SIGMAR1MAPTKDM4EMEN1ALDH1A1 | |
| SCHEMBL20258331 | 0.67 | LMNA (0.40) | SIGMAR1MEN1CYP3A4ALOX15KMT2A | |
| SCHEMBL22305046 | 0.67 | LMNA (0.40) | SIGMAR1MEN1CYP3A4ALOX15KMT2A | |
| SCHEMBL23386045 | 0.67 | SIGMAR1 (0.51) | SIGMAR1MAPTKDM4EMEN1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140171454-A1 | Substituted Pyrrolo[2,3-d]pyrimidines as Inhibitors of Protein Kinases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-06-19 | — | — | US | disclosed |
| US-8633205-B2 | Substituted pyrrolo[2,3-d]pyrimidines as inhibitors of protein kinases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-01-21 | — | — | US | disclosed |
| US-20070004762-A9 | Pyrrolopyrimidines useful as inhibitors of protein kinase | VERTEX PHARMACEUTICALS INCORPORATED | 2007-01-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070004762-A9 | Pyrrolopyrimidines useful as inhibitors of protein kinase | PRKDC, MAP3K20, MAP3K5 | SIGMAR1 4607/4885MAPT 1300/4885KDM4E 1549/4885 |
| US-20140171454-A1 | Substituted Pyrrolo[2,3-d]pyrimidines as Inhibitors of Protein Kinases | PRKDC, DCK, CDK2 | SIGMAR1 4677/4885MAPT 1444/4885KDM4E 1255/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.